Corrigendum to “Neuroendocrine biomarkers of prolonged exposure treatment response in military-related PTSD” [Psychoneuroendocrinology (2020) Article 104749] (Psychoneuroendocrinology (2020) 119, (S0306453020301682), (10.1016/j.psyneuen.2020.104749))

For the Consortium to Alleviate PTSD and the STRONG STAR Consortium

Research output: Contribution to journalComment/debate

Abstract

The authors regret that our previously published results included an error in the data of one patient that occurred during data migration that impacts the longitudinal modelling reported for Study 2. Abstract sentence should read: “We found that higher cortisol reactivity during script-driven imagery was associated with higher baseline PTSD severity and that baseline allopregnanolone, pregnanolone, and cortisol reactivity were associated with PTSD treatment responder status over the course of intensive outpatient treatment.” Section 3.1 Methods end of first paragraph should read: >“…., and 3) high responders, i.e., those with post PCL-5 less than 33, will have lower cortisol response to startle and higher allopregnanolone and DHEA(S).” Section 3.3 Results third paragraph should read: “To determine whether these biomarkers predicted treatment response, we examined whether baseline biomarkers were related to the slope of change in the PCL-5 across treatment. Smaller baseline AUCg during the startle paradigm predicted steeper slope of change in PCL scores, β = 2.06, SE = 0.69, p < .003. Figure 2 illustrates this effect by graphing estimated change in PCL for those in the low, middle, or high third of the sample in terms of AUCg values during the startle paradigm. Higher baseline levels of allopregnanolone did not predict slope of change in PCL scores across treatment, β = -0.93, SE = 070, p = .19. Baseline pregnanolone also did not predict slope in PCL scores, β = -1.69, SE = 1.28, p = .19. No other biomarkers predicted slope.” Section 3.3 Results fifth paragraph should read: “Given the potential influence of a primary diagnosis of PTSD versus another primary diagnosis, we repeated the analyses with a subsample with a primary diagnosis of PTSD only (n = 168; 80 %).” Figure 3 should be removed as it depicts a non-significant effect. Discussion, 4th paragraph, sentence starting “In addition,.” should read: “In addition, male responders showed higher baseline allopregnanolone and pregnanolone than male nonresponders to treatment.” The authors also acknowledge the contribution of Dr. Carly Yasinski, Emory University School of Medicine who provided an independent review of all modelling results. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Article number104802
JournalPsychoneuroendocrinology
Volume120
DOIs
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Corrigendum to “Neuroendocrine biomarkers of prolonged exposure treatment response in military-related PTSD” [Psychoneuroendocrinology (2020) Article 104749] (Psychoneuroendocrinology (2020) 119, (S0306453020301682), (10.1016/j.psyneuen.2020.104749))'. Together they form a unique fingerprint.

Cite this